Corcione N, Biondi-Zoccai G, Ferraro P, et al. - Researchers assessed long-term outcomes (major adverse events: the composite of death, stroke, myocardial infarction, major vascular complication or major bleeding) of 2 leading transcatheter aortic valve implantation (TAVI) devices (Evolut and Portico) used by the same team of experienced TAVI operators, to ultimately determine the safety as well as the efficacy of these devices. This study included 233 patients, 119 (51.1%) receiving Evolut and 114 (49%) receiving Portico. Significant between-device differences were shown by baseline and procedural data, including functional class, surgical risk, chronic obstructive pulmonary disease, renal function, transesophageal guidance, device size, postdilation, and procedural time. Yet, there was no significant variation in acute and in-hospital results. For major adverse events, as well as for the individual risk of mortality, stroke, myocardial infarction, major vascular complication, major bleeding, and pacemaker implantation, similar rates were shown in unadjusted analysis. No significantly different outcomes were achieved with Evolut and Portico even at propensity score-adjusted analysis. Experts found that similarly favorable outcomes were provided by Evolut and Portico devices at long-term follow-up when used by experienced TAVI operators.